Zazove Associates’s Revance Therapeutics, Inc. RVNC Stock Holding History

Zazove Associates’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-85,724	Closed	-$1.19M	–	177
2022 Q2	$1.19M	Hold	85,724	–	–	0.11%	106
2022 Q1	$1.67M	Buy	+85,724	New	+$1.3M	0.15%	94
2021 Q3	$3.91M	Buy	140,430 +88,195	+169%	+$2.52M	0.34%	56
2021 Q2	$1.55M	Hold	52,235	–	–	0.14%	91
2021 Q1	$1.46M	Buy	52,235 +45,907	+725%	+$1.27M	0.17%	78
2020 Q4	$179K	Buy	+6,328	New	+$164K	0.02%	106

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Zazove Associates's RVNC Position: Q3 2022 in Review

Zazove Associates sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2022, closing a stake of 85,724 shares — an estimated $1.19M sold.

Zazove Associates first reported a position in RVNC in Q4 2020 and held it in 6 quarters. The position peaked at $3.91M in Q3 2021. 182 funds tracked by Wall St. Rank hold RVNC as of Q3 2022.

Zazove Associates reported no remaining Revance Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Zazove Associates sold 85,724 Revance Therapeutics, Inc. shares in Q3 2022, an estimated $1.19M.
Zazove Associates first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 6 quarters.
Zazove Associates's Revance Therapeutics, Inc. position peaked at $3.91M in Q3 2021.
182 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2022.

Based on Zazove Associates's 13F filing for Q3 2022, filed 24 Oct 2022.